Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Authors

Natasha B Leighl, Princess Margaret Hospital Cancer Centre
Jeffrey D Bradley, Washington University School of Medicine in St. Louis
et al

Journal

Journal for Immunotherapy of Cancer

Publication Date

8-1-2021

Volume

9

Issue

8

First Page

e002973

Document Type

Open Access Publication

DOI

10.1136/jitc-2021-002973

Rights and Permissions

Leighl NB, Redman MW, Rizvi N, et alPhase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Journal for ImmunoTherapy of Cancer 2021;9:e002973. doi: 10.1136/jitc-2021-002973 https://jitc.bmj.com/content/9/8/e002973 © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Leighl, Natasha B; Bradley, Jeffrey D; and et al, "Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)." Journal for Immunotherapy of Cancer. 9, 8. e002973 (2021).
https://digitalcommons.wustl.edu/oa_4/115